CN110050075B - 用于确定特定癌症的癌症疗法的功效的血液样品的数字分析 - Google Patents

用于确定特定癌症的癌症疗法的功效的血液样品的数字分析 Download PDF

Info

Publication number
CN110050075B
CN110050075B CN201780075515.XA CN201780075515A CN110050075B CN 110050075 B CN110050075 B CN 110050075B CN 201780075515 A CN201780075515 A CN 201780075515A CN 110050075 B CN110050075 B CN 110050075B
Authority
CN
China
Prior art keywords
cancer
ctc
cdna
ctcs
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780075515.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN110050075A (zh
Inventor
D.哈伯
S.马赫斯瓦兰
T.托多罗瓦
M.卡利尼奇
D.T.米亚莫托
X.洪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Publication of CN110050075A publication Critical patent/CN110050075A/zh
Application granted granted Critical
Publication of CN110050075B publication Critical patent/CN110050075B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
CN201780075515.XA 2016-10-27 2017-10-27 用于确定特定癌症的癌症疗法的功效的血液样品的数字分析 Active CN110050075B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662413952P 2016-10-27 2016-10-27
US62/413,952 2016-10-27
PCT/US2017/058855 WO2018081625A2 (en) 2016-10-27 2017-10-27 Digital analysis of blood samples to determine efficacy of cancer therapies for specific cancers

Publications (2)

Publication Number Publication Date
CN110050075A CN110050075A (zh) 2019-07-23
CN110050075B true CN110050075B (zh) 2024-04-02

Family

ID=62025512

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780075515.XA Active CN110050075B (zh) 2016-10-27 2017-10-27 用于确定特定癌症的癌症疗法的功效的血液样品的数字分析

Country Status (5)

Country Link
US (2) US11371101B2 (enExample)
EP (2) EP3985127A1 (enExample)
JP (2) JP7195252B2 (enExample)
CN (1) CN110050075B (enExample)
WO (1) WO2018081625A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016238253B2 (en) 2015-03-25 2022-06-16 The General Hospital Corporation Digital analysis of circulating tumor cells in blood samples
WO2018081625A2 (en) * 2016-10-27 2018-05-03 The General Hospital Corporation Digital analysis of blood samples to determine efficacy of cancer therapies for specific cancers
WO2020006098A2 (en) * 2018-06-26 2020-01-02 Children's National Medical Center Tumor-associated markers for detection of minimal residual disease using digital droplet pcr
US12358918B2 (en) 2018-11-14 2025-07-15 The Broad Institute, Inc. Aryl hydrocarbon receptor (AHR) activator compounds as cancer therapeutics
TWI790399B (zh) * 2019-08-30 2023-01-21 長庚大學 循環腫瘤細胞資訊評估方法及其分析方法
CN114830258A (zh) * 2019-09-16 2022-07-29 斯坦福大学托管董事会 基于乳腺癌的分子表征的治疗方法
CN112698033A (zh) * 2020-12-09 2021-04-23 复旦大学附属中山医院 一种血源性外泌体her2的检测方法及其应用
WO2022196186A1 (ja) * 2021-03-16 2022-09-22 ソニーグループ株式会社 閉鎖系の自動試料分取システム
CN113292643A (zh) * 2021-05-31 2021-08-24 南京市第二医院 一种肝癌肿瘤标志物及其应用
JP2024527371A (ja) * 2021-07-08 2024-07-24 オウロテック インコーポレイテッド 処置の有効性予測システム及び方法
CN114395622A (zh) * 2021-12-13 2022-04-26 深圳先进技术研究院 一种利用数字pcr检测循环肿瘤细胞egfr基因突变的方法及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012135397A2 (en) * 2011-03-29 2012-10-04 Lisanti Michael P Lactate-and ketones-induced gene signatures and use the same for diagnosing disease and predicting clinical outcome
AU2015268617A1 (en) * 2010-03-31 2016-01-07 Sividon Diagnostics Gmbh Method for breast cancer recurrence prediction under endocrine treatment
WO2016154600A1 (en) * 2015-03-25 2016-09-29 The General Hospital Corporation Digital analysis of circulating tumor cells in blood samples

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8535A (en) 1851-11-18 Stove-geate
US889A (en) 1838-08-20 Mode of constructing metal bench-vises
DE29623597U1 (de) 1996-11-08 1999-01-07 Eppendorf - Netheler - Hinz Gmbh, 22339 Hamburg Temperierblock mit Temperiereinrichtungen
US20080050393A1 (en) 1998-12-03 2008-02-28 Tang Y Tom Novel nucleic acids and polypeptides
CA2311201A1 (en) 1999-08-05 2001-02-05 Genset S.A. Ests and encoded human proteins
CA2430981A1 (en) 2000-12-08 2002-06-13 Francois Bertucci Gene expression profiling of primary breast carcinomas using arrays of candidate genes
US20030064385A1 (en) 2001-05-16 2003-04-03 Dressman Marlene Michelle Genes expressed in breast cancer as prognostic and therapeutic targets
US20030073623A1 (en) 2001-07-30 2003-04-17 Drmanac Radoje T. Novel nucleic acid sequences obtained from various cDNA libraries
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
US20060275794A1 (en) 2005-03-07 2006-12-07 Invitrogen Corporation Collections of matched biological reagents and methods for identifying matched reagents
US20070026417A1 (en) 2005-07-29 2007-02-01 Martin Fuchs Devices and methods for enrichment and alteration of circulating tumor cells and other particles
WO2006121991A2 (en) * 2005-05-06 2006-11-16 Diadexus, Inc. Compositions and methods for detection, prognosis and treatment of breast cancer
CA2652052A1 (en) 2006-05-16 2007-11-29 Nugen Technologies, Inc. Nucleic acid separation and purification method based on reversible charge interactions
EP2589668A1 (en) 2006-06-14 2013-05-08 Verinata Health, Inc Rare cell analysis using sample splitting and DNA tags
WO2009051734A1 (en) 2007-10-17 2009-04-23 The General Hospital Corporation Microchip-based devices for capturing circulating tumor cells and methods of their use
US9068181B2 (en) 2008-05-23 2015-06-30 The General Hospital Corporation Microfluidic droplet encapsulation
US20120252015A1 (en) 2011-02-18 2012-10-04 Bio-Rad Laboratories Methods and compositions for detecting genetic material
WO2010037134A2 (en) 2008-09-29 2010-04-01 Stemlifeline, Inc. Multi-stage stem cell carcinogenesis
US9625454B2 (en) 2009-09-04 2017-04-18 The Research Foundation For The State University Of New York Rapid and continuous analyte processing in droplet microfluidic devices
US20110166030A1 (en) 2009-09-30 2011-07-07 Yixin Wang Prediction of response to docetaxel therapy based on the presence of TMPRSSG2:ERG fusion in circulating tumor cells
EP4484577A3 (en) 2010-02-12 2025-03-26 Bio-Rad Laboratories, Inc. Digital analyte analysis
WO2011112903A2 (en) 2010-03-11 2011-09-15 Board Of Regents, The University Of Texas System Quantitative rt-pcr detection for genes involved in epithelial mesenchymal transition in peripheral blood of breast cancer patients
HUE030164T2 (en) * 2010-03-31 2017-05-29 Sividon Diagnostics Gmbh A method of predicting breast cancer recurrence during endocrine treatment
US9650629B2 (en) 2010-07-07 2017-05-16 Roche Molecular Systems, Inc. Clonal pre-amplification in emulsion
EP2606353A4 (en) * 2010-08-18 2014-10-15 Caris Life Sciences Luxembourg Holdings CIRCULATING BIOMARKERS FOR DISEASE
EP2678448A4 (en) 2011-02-22 2014-10-01 Caris Life Sciences Luxembourg Holdings S A R L CIRCULATING BIOMARKERS
US8841071B2 (en) 2011-06-02 2014-09-23 Raindance Technologies, Inc. Sample multiplexing
JP6247218B2 (ja) 2011-10-24 2017-12-13 ザ ジェネラル ホスピタル コーポレイション 癌のバイオマーカー
US9766244B2 (en) * 2012-07-02 2017-09-19 The General Hospital Corporation Diagnosis and monitoring treatment of prostate cancer
CN110643681A (zh) 2012-08-13 2020-01-03 加利福尼亚大学董事会 用于检测生物组分的方法和系统
AU2013315128B2 (en) * 2012-09-14 2019-01-03 Memorial Sloan-Kettering Cancer Center Genes associated with dasatinib sensitivity
WO2014047285A1 (en) 2012-09-19 2014-03-27 Paraskevi Giannakakou Identifying taxane sensitivity in prostate cancer patients
WO2014075067A1 (en) * 2012-11-12 2014-05-15 Nanostring Technologies, Inc. Methods to predict breast cancer outcome
WO2014165762A1 (en) 2013-04-05 2014-10-09 Raindance Technologies, Inc. Rare cell analysis after negative selection
JP2016528252A (ja) 2013-08-12 2016-09-15 トーカイ ファーマシューティカルズ， インコーポレイテッド アンドロゲン標的治療を使用する新生物障害の処置のためのバイオマーカー
EP3058316B1 (en) 2013-10-18 2019-03-13 The General Hospital Corporation Microfluidic sorting using high gradient magnetic fields
BR112016020953A2 (pt) * 2014-03-13 2018-01-23 Hoffmann La Roche composto, kit, composição farmacêutica, uso de composto, método de tratamento e invenção
WO2015177184A1 (en) * 2014-05-21 2015-11-26 F. Hoffmann-La Roche Ag Methods of treating pr-positive, luminal a breast cancer with pi3k inhibitor, pictilisib
DK3230736T3 (da) * 2014-12-12 2020-06-08 Celcuity Inc Fremgangsmåder til måling af ErbB-signaleringsvejsaktivitet til at diagnosticere og behandle cancerpatienter
ES2719206T3 (es) 2015-02-20 2019-07-09 Comelz Spa Procedimiento para cortar pieles naturales
CN107567502A (zh) 2015-03-12 2018-01-09 詹森药业有限公司 用于预测前列腺癌的基于全血的mrna标记物和检测该mrna标记物的方法
WO2018081625A2 (en) * 2016-10-27 2018-05-03 The General Hospital Corporation Digital analysis of blood samples to determine efficacy of cancer therapies for specific cancers

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015268617A1 (en) * 2010-03-31 2016-01-07 Sividon Diagnostics Gmbh Method for breast cancer recurrence prediction under endocrine treatment
WO2012135397A2 (en) * 2011-03-29 2012-10-04 Lisanti Michael P Lactate-and ketones-induced gene signatures and use the same for diagnosing disease and predicting clinical outcome
WO2016154600A1 (en) * 2015-03-25 2016-09-29 The General Hospital Corporation Digital analysis of circulating tumor cells in blood samples

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
雌激素受体阳性乳腺癌他莫昔芬耐药机制的研究进展;柳慧星等;《肿瘤》;20150925;第35卷(第09期);第1039-1044页 *

Also Published As

Publication number Publication date
EP3532642A4 (en) 2020-06-24
US11371101B2 (en) 2022-06-28
JP7441907B2 (ja) 2024-03-01
JP2020501517A (ja) 2020-01-23
WO2018081625A3 (en) 2018-06-07
US20220364185A1 (en) 2022-11-17
EP3532642B1 (en) 2021-12-08
WO2018081625A2 (en) 2018-05-03
US12331363B2 (en) 2025-06-17
JP7195252B2 (ja) 2022-12-23
JP2022184902A (ja) 2022-12-13
EP3532642A2 (en) 2019-09-04
CN110050075A (zh) 2019-07-23
EP3985127A1 (en) 2022-04-20
US20190391134A1 (en) 2019-12-26

Similar Documents

Publication Publication Date Title
CN110050075B (zh) 用于确定特定癌症的癌症疗法的功效的血液样品的数字分析
US20240132969A1 (en) Digital Analysis of Circulating Tumor Cells in Blood Samples
CN104093859A (zh) 多基因生物标志物的鉴定
Parsons et al. Circulating plasma tumor DNA
CN106795557A (zh) 用于肺癌诊断的方法和系统
CN110806480A (zh) 肿瘤特异性细胞亚群和特征基因及其应用
CN110747275B (zh) 肿瘤细胞标记分子及其应用
JP2025502633A (ja) 無痛形態から侵襲性前立腺ガンを検出するバイオマーカーおよびその治療
Lianidou et al. Development and validation of molecular assays for liquid biopsy applications
EP3426797A1 (en) Method for determining the risk of recurrence of an estrogen receptor-positive and her2-negative primary mammary carcinoma under an endocrine therapy
Škereňová Individualization of the treatment of prostate cancer patients based on the immunocytochemical detection of circulating tumor cells
Telkoparan Akillilar et al. Role of Circulating Tumor Cells and Cell-Free Tumor Deoxyribonucleic Acid Fragments as Liquid Biopsy Materials in Breast Oncology.
HK1249553B (en) Digital analysis of circulating tumor cells in blood samples
HK1213297B (zh) 用於檢測和測定前列腺癌預後的組合物和方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant